What can be Improved Upon for Existing Drugs?

9:00 am - Thursday 10th September 2026

  • Discussing approaches to differentiate assets targeting competitive targets
  • With clinical data so far, what constitutes a good outcome in autoimmune disease and which approach gets you there?
  • Protocol design to define initial target indications, strategizing how to rapidly generate early clinical, proof-of-concept data, and differentiating company assets within competitive landscapes

Speakers:

Senior Director
UCB
Founder & Chief Executive Officer
Kali Therapeutics
President, Chief Executive Officer, Director & Co-founder
IN8Bio
Co-Founder & Scientific Director
Ajaya Bio